This content is for informational and educational purposes only. Peptides discussed on this page are research compounds not approved by the FDA for human use. Always consult a licensed medical professional before using any peptide or supplement.

Microdosing Retatrutide: Split Dosing Schedules, Pharmacokinetics & Calculator (2026)

Microdosing retatrutide — splitting a standard weekly dose into two or three smaller injections — has gained traction in the research community as a strategy to reduce peak-related side effects without sacrificing efficacy. This guide covers the pharmacokinetic rationale, exact example schedules, a head-to-head comparison of 1×, 2×, and 3× weekly dosing, and the pros and cons of each approach.

Quick Answer: What Is Microdosing Retatrutide?

Microdosing retatrutide means dividing your total weekly dose across 2–3 injections instead of one. A 6 mg weekly dose, for example, becomes 3 mg every Monday and Thursday. Because retatrutide has a ~6-day half-life, splitting the dose flattens the concentration curve — reducing peak levels by an estimated 28–38% while maintaining roughly the same average (trough) exposure. No clinical trials have validated this approach; the evidence is pharmacokinetic modelling combined with community experience. It is not an officially recommended protocol.

Why People Microdose Retatrutide

Retatrutide is a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — which contributes to its exceptional potency but also to its side-effect profile at higher doses. GI adverse events (nausea, vomiting, delayed gastric emptying) in the Phase 2 NEJM 2023 trial were dose-dependent and most pronounced in the first 24–48 hours after each injection — i.e., at peak drug concentration.

The logic behind microdosing is simple: if side effects cluster around the post-injection peak, flattening that peak should reduce their severity. This is the same rationale used successfully in insulin therapy (multiple daily injections vs. once-daily basal) and in growth hormone protocols. Whether it applies equally to long-acting GLP/GIP agonists is plausible but unproven.

A secondary motivation is cost flexibility: users titrating cautiously may wish to dial in at sub-milligram precision, particularly in the early weeks of a protocol.

Retatrutide Pharmacokinetics: The Foundation

Understanding why split dosing can work requires a basic grasp of retatrutide's pharmacokinetic (PK) profile.

• Half-life: ~6 days (terminal elimination half-life). This is unusually long for a peptide — it results from fatty acid conjugation that enables albumin binding, similar to semaglutide's mechanism.
• Time to steady state: 4–5 weeks of once-weekly dosing (approximately 4–5 half-lives).
• Peak-to-trough (P/T) ratio at once-weekly dosing: Approximately 1.8–2.0. This means peak concentration is roughly twice the trough concentration, creating a "sawtooth" curve across the week.
• Subcutaneous bioavailability: ~65–75%, with slow absorption from the injection depot contributing to a blunted Cmax vs. IV administration.
• Time to peak (Tmax): 24–72 hours post-injection, depending on injection site and formulation.

When you split a weekly dose into two injections, each dose is half as large, so the individual peaks are lower. Because retatrutide's half-life is much longer than a week, significant drug levels remain from the previous injection when the next dose is given — this "background level" forms a higher floor (trough), further reducing the relative swing between peak and trough.

The net result: twice-weekly dosing reduces the P/T ratio from ~2.0 to approximately 1.4–1.5, representing a ~28% reduction in peak concentration. Three-times-weekly dosing pushes the P/T ratio to roughly 1.3, a ~35% peak reduction. See the full retatrutide dosage chart for concentration curves at each frequency.

Dosing Frequency Comparison: 1× vs 2× vs 3× Weekly

The table below compares the three most practical microdosing frequencies using a 6 mg/week total dose as the example. Figures are based on pharmacokinetic modelling; individual results will vary.

Metric	1× Weekly (Standard)	2× Weekly (Split)	3× Weekly (Mon/Wed/Fri)
Dose per injection	6 mg	3 mg	2 mg
Injection days (example)	Monday	Monday + Thursday	Mon / Wed / Fri
Peak-to-trough ratio	~1.9	~1.4–1.5	~1.3
Peak concentration reduction	Baseline	~28%	~35%
Injections per week	1	2	3
Weekly dose total	6 mg	6 mg	6 mg
Steady-state timing	4–5 weeks	4–5 weeks	4–5 weeks
Nausea risk (theoretical)	Higher	Moderate	Lower
Complexity	Low	Moderate	Higher
Clinical trial validation	Yes (Phase 2)	No	No

Note: All figures are modelled estimates. Use the microdosing calculator to generate curves for your specific dose and titration stage.

Example Microdosing Schedules with Exact Doses

Below are three practical microdosing protocols mirroring the Phase 2 trial titration (2 mg → 4 mg → 8 mg/week equivalent). Choose a frequency and stick with consistent injection days each week.

Schedule A: Twice-Weekly (Most Popular)

Split each week's dose into two equal injections, Monday and Thursday (roughly 3–4 days apart).

1. Weeks 1–4: 1 mg Monday + 1 mg Thursday = 2 mg/week total
2. Weeks 5–8: 2 mg Monday + 2 mg Thursday = 4 mg/week total
3. Weeks 9–12: 3 mg Monday + 3 mg Thursday = 6 mg/week total
4. Weeks 13–16: 4 mg Monday + 4 mg Thursday = 8 mg/week total
5. Maintenance: Hold at 4 mg × 2 or reduce to 2 mg × 2 based on response

This is the most widely used microdosing schedule because it mirrors insulin twice-daily logic, fits naturally into a work week, and the 3–4 day spacing prevents injections from stacking too closely.

Schedule B: Three-Times-Weekly (Mon / Wed / Fri)

Split each week's dose across three equal injections on non-consecutive days.

1. Weeks 1–4: ~0.67 mg Mon + 0.67 mg Wed + 0.67 mg Fri = 2 mg/week
2. Weeks 5–8: ~1.33 mg Mon + 1.33 mg Wed + 1.33 mg Fri = 4 mg/week
3. Weeks 9–12: 2 mg Mon + 2 mg Wed + 2 mg Fri = 6 mg/week
4. Weeks 13–16: ~2.67 mg Mon + 2.67 mg Wed + 2.67 mg Fri = 8 mg/week

Note that doses like 0.67 mg and 1.33 mg require precise volumetric measurement. Use the dose calculator to convert mg to volume based on your vial concentration. A 10 mg/mL vial makes these calculations more manageable than a 5 mg/mL concentration.

Schedule C: Standard Weekly (Clinical Baseline — No Microdosing)

Included for reference. This mirrors the Phase 2 trial protocol exactly.

1. Weeks 1–4: 2 mg every Monday
2. Weeks 5–8: 4 mg every Monday
3. Weeks 9–12: 8 mg every Monday
4. Weeks 13+: 12 mg every Monday (max trial dose) or hold at 8 mg

The standard weekly protocol has the clinical evidence behind it. If tolerability at once-weekly dosing is acceptable, there is no proven reason to switch to split dosing.

Pros and Cons of Microdosing Retatrutide

Potential Benefits

• Reduced peak nausea: GI side effects in GLP-1/GIP agonists are concentration-dependent at the receptor level. Lower post-injection peaks theoretically translate to milder nausea, especially in weeks 1–8 of titration.
• Smoother energy and appetite suppression: Users report that the appetite-suppressing effect feels more consistent across the week with split dosing, rather than strong the first few days post-injection and weaker by day 6–7.
• Flexible dose increments: Splitting allows finer-grained titration. If 4 mg/week causes side effects but 2 mg/week isn't enough, splitting to 1.5 mg twice weekly gives a 3 mg/week total that isn't achievable with once-weekly dosing without cutting doses awkwardly.
• Precedent from analogous therapies: Insulin, growth hormone, and GnRH analogues are all administered more frequently than their half-lives would strictly require, specifically to flatten concentration peaks. The pharmacokinetic principle is well-established.

Drawbacks and Risks

• No clinical validation: Every piece of evidence for split-dose retatrutide is theoretical or anecdotal. There are no RCTs, no dose-finding studies, and no safety data for this approach.
• Injection site accumulation: More frequent injections increase cumulative injection-site exposure. Rotating sites becomes more critical — and more complex to track.
• Measurement precision required: Three-times-weekly doses (e.g., 1.33 mg) demand accurate volumetric measurement. Errors in reconstitution or drawing volume are amplified when each injection is small.
• Efficacy may not be preserved at lower weekly totals: If someone mistakenly keeps each individual injection at the standard weekly dose (e.g., 2 mg × 3 = 6 mg total vs. the intended 2 mg weekly), they triple their total weekly dose, which is dangerous. Clear math is essential.
• Psychological overhead: Managing a three-times-weekly schedule adds cognitive load — tracking doses, days, injection sites, and reconstituted vial volumes. Some users find this error-prone.

Important: When microdosing, the total weekly dose stays the same — you are splitting it, not multiplying it. A 6 mg/week protocol split twice-weekly = 3 mg Monday + 3 mg Thursday. It does NOT mean 6 mg Monday + 6 mg Thursday.

Using a Microdosing Calculator

Manually computing concentration curves across a 12–20 week titration is tedious and error-prone. The PeptideDeck microdosing calculator lets you:

• Input your total weekly dose and injection frequency
• Visualize the simulated plasma concentration curve over time
• Compare peak-to-trough ratios between 1×, 2×, and 3× weekly dosing
• Estimate time to steady state at your chosen frequency
• Convert mg doses to injection volumes based on your vial concentration

For volume-to-dose conversions at a single point in time, the general-purpose dose calculator is faster. Both tools are free and require no account.

For broader context on titration stages, see the retatrutide dosage chart, which covers the full 2 mg → 12 mg titration ladder with timing guidance.

Who Should Consider Microdosing?

Split dosing may be worth considering if:

• You experience significant nausea or vomiting in the 24–48 hours after each weekly injection
• You notice a strong "on/off" pattern — feeling the drug heavily the first 3 days and then feeling it wear off by day 6–7
• You are titrating conservatively and want intermediate dose options not achievable with once-weekly injection
• You have experience with other peptide or hormone protocols and are comfortable with multi-injection routines

Split dosing is probably not necessary if:

• You tolerate once-weekly injections without significant side effects
• You prefer simplicity and reduced injection burden
• You are new to peptide use and want to stick to the protocol closest to clinical trial data

Frequently Asked Questions

Does splitting the dose reduce retatrutide's effectiveness?

Pharmacokinetic modelling suggests that average (AUC) exposure is maintained when the total weekly dose stays constant, regardless of how many injections it is split into. However, very frequent small doses could theoretically affect receptor desensitization dynamics differently than less frequent larger doses. Without clinical data, the efficacy question for split dosing cannot be definitively answered.

Can I split a single vial into multiple small doses?

Yes, as long as you track volumes carefully and maintain sterile technique. Reconstituted retatrutide is typically stable in a vial for 28–30 days when refrigerated at 2–8°C. Draw each dose from the same vial until it is empty, then open the next. Never pool reconstituted peptide across vials.

What vial concentration works best for microdosing?

Higher concentrations (10 mg/mL) are generally more practical for microdosing because smaller injection volumes are required to deliver precise doses. At 5 mg/mL, a 0.67 mg dose requires only 0.13 mL — at the edge of accurate measurement with an insulin syringe. At 10 mg/mL, the same 0.67 mg dose is 0.067 mL, which is even harder to draw accurately. Consider reconstituting at a concentration that places your target dose in the 0.1–0.5 mL range.

Does the injection day matter for split dosing?

Consistency is more important than the specific days chosen. For twice-weekly dosing, aim for roughly equal spacing (e.g., 3–4 days apart). For three-times-weekly, Monday/Wednesday/Friday provides clean 48-hour spacing. Avoid injecting two doses within 24 hours of each other.

Is there any clinical or research evidence supporting microdosing retatrutide specifically?

No. The Phase 2 and ongoing Phase 3 trials use once-weekly dosing exclusively. All split-dose evidence is extrapolated from PK modelling, analogous therapies (insulin, GH, semaglutide community reports), and anecdotal user data. This does not mean it is unsafe or ineffective — it means the evidence base is weak and caution is warranted.

How do I know if microdosing is working better than weekly dosing?

Track your side-effect severity in the 48 hours post-injection (nausea score, appetite suppression, energy), your average weekly appetite suppression, and any weight changes. If you previously used once-weekly and switched to split dosing, compare these metrics across both phases. The microdosing calculator can help you visualize whether your simulated concentration curve has meaningfully flattened.

Can I microdose during the titration phase only, then switch to once-weekly at maintenance?

This is a common approach in the community. Titration is when peak-related side effects are most variable (the drug is still approaching steady state and doses are actively increasing). Once at a stable maintenance dose, some users find that switching to once-weekly is tolerable. The reverse — starting weekly and switching to split dosing if side effects emerge — is equally valid.

This content is for informational and educational purposes only. Peptides discussed on this page are research compounds not approved by the FDA for human use. Always consult a licensed medical professional before using any peptide or supplement.